Teclistamab

The combination of talquetamab and teclistamab induced durable responses among patients with relapsed or refractory multiple myeloma, according to phase 1B/phase 2 study results.

More than 20% of reported cases of adverse events following bispecific T-cell engager therapies involved a cardiovascular event, findings reported in Journal for ImmunoTherapy of Cancer showed.

The last year has seen important FDA approvals for the treatment of multiple myeloma and the upcoming year promises updates from ongoing clinical trials.

In this video, Nihkil Munshi, MD, Professor of Medicine at Harvard Medical School, discusses the proliferation of new drugs to treat multiple myeloma and how they have changed the standard of care for the disease.

Although multiple myeloma remains incurable, treatment advances during the past several years have dramatically improved clinicians’ ability to slow progression of the disease.

NEW ORLEANS — A novel combination induced response among patients with pretreated multiple myeloma, according to study results presented at ASH Annual Meeting and Exposition.

NEW ORLEANS — In this video perspective, Nikhil C. Munshi, MD, discusses presentations from the ASH Annual Meeting and Exposition that focus on advances in bispecific antibody treatments for patients with multiple myeloma.

The FDA granted accelerated approval to teclistamab-cqyv for treatment of certain patients of myeloma.

CHICAGO — Teclistamab continued to demonstrate durable efficacy for patients with relapsed or refractory multiple myeloma, according to results from the phase 1/phase 2 MajesTEC-1 trial.